Making waves with new directions – there are many possible ways to go when considering targeting the adenosine axis
As we segue between our AACR and ASCO coverage, one topic that straddles both virtual meetings is targeting the adenosine axis. At AACR19, this pathway was very much front and square with some intriguing and controversial data presented, which caught many people by surprise.
Since then, several companies have opened new trials, others are completing enrollment and waiting for their data to readout before deciding upon next steps.
It’s a good time to take a look at what’s new in this niche and also see things differently through the lens of one company involved in the field. Yes, it’s time to share our latest expert interview from not one, but two, c-suite executives.
What are their perspectives (they are different), where do they see the field going and why?
In part one of the discussion we focus exclusively on adenosine targeting and how they see themselves differentiated from the crowd… it certainly makes for interesting reading!
To learn more from our oncology analysis and get a heads up on insights and commentary on the adenosine axis subscribers can log-in or you can click to gain access to BSB Premium Content.
Some of the upcoming coming small biotechs caught our attention and may turn out to be future stars
National Harbor – There were quite a few gems in the poster halls and oral presentations from up and coming small cap biotechs at the Society for Immunotherapy of Cancer (SITC) meeting this year.
Who were they and what did we learn from them?
In the latest part of our latest SITC coverage we highlight 13 presentations – 11 from small biotechs and 2 academic abstracts – that caught our attention, explain what’s intriguing about them and why they matter.
There’s not a single big Pharma included (unless as a reference point or given in combination) since the focus is mainly on up and coming companies with their novel approaches.
The list is quite selective and not at all random from a list of over 850 abstracts.
So what stood out and what was special about them?
Some of the selections are likely hidden sleepers that few will be familiar with… they also cover a wide range of approaches, targets, different modalities and even strategic intent.
Even if you were at the SITC 2019 meeting, increasingly there were more business meetings taking up valuable time than sessions attended, so this is a great way to catch all the highlights for your trip report 😉
To learn more from our oncology coverage and get a heads up on our latest insights from the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
The AACR19 ‘mosh pit’ where gems abound
It’s been a while since we looked at the adenosine pathway, where a fog of immunosuppression is thought to cloak the ability of the immune system to induce antitumour immunity.
When we first wrote about the A2A receptor-CD73-CD39 pathway in 2016 there really weren’t very many players in this niche. Since then the field has expanded quite considerably and there are now more companies and molecules to consider.
As we straddle AACR and ASCO, it’s a great time to offer an update and look at what we learned…
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
National Harbor, MD – Day 2 of #SITC17 brought some interesting highlights on a number of fronts, not all of which may be apparent at present, but there are a few readouts that will have a broader impact going forward.
SITC 2017 Stars?
As we move into an era where we see more combinations evolve in immuno-onology, things are likely to get more confusing rather than less so and it could well be another 3-5 years before things truly settle down and more concrete trends emerge.
Here, we reviewed 10 different areas of interest with a strong clinical relevance and explored the topics further.
Please note that some of these will also have follow-on posts with thought leader interviews and related poster reviews.
To learn more insights on the latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
With the annual meeting of Society for Immunotherapy of Cancer (SITC) fast approaching this week, it’s time for a look at some of the final highlights to watch out for.
In this latest conference preview, we have chosen a dozen key topics of interest that readers may find worth checking out plus an honourable mention for early compounds in development that we may well hear more about going forward.
Some of the early warning signs were offered up in the earlier Previews and with the abstracts now available, things are getting very interesting indeed…
How are things panning out so far with the abstract drop and are the new products in development living up to the hype and expectations?
To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.
Waiting in line for the White House Tour
The 2017 annual meeting of the American Association for Cancer Research in Washington DC (Twitter #AACR17) officially starts tomorrow, but today was a day full of educational sessions and workshops.
After a day of rain yesterday, it was good to have a dry day for the start of the world’s leading cancer science meeting.
In this post we offer some top-line commentary on those educational sessions we attended; the choice reflects personal interests or current fetishes.
By definition, there is far more excellent research at AACR than we can possibly cover on the blog; so we encourage you to check out the AACR webcasts if you have a specific interest or want to check out a particular session.
We’d also like to congratulate AACR for moving with the times and allowing personal photography and the sharing of content on social media, except where a slide or presentation says “Do Not Post.”
The few slides that I saw today that had “Do Not Post” showed unpublished data. Our longstanding unwritten policy has been not to tweet or share on social media data that clearly states it is unpublished, so this was not an unreasonable request and one we heartily concur with in principle.
Subscribers can login to read more